Naproxen / Esomeprazole (Vimovo)
NSAID with proton pump inhibitor (fixed-dose combination)
Naproxen / Esomeprazole (Vimovo)
Forms and strengths
Form: TabletStrength: 375 mg naproxen / 20 mg esomeprazole, 500 mg naproxen / 20 mg esomeprazole
References
Indication
- Vimovo treats the signs and symptoms of osteoarthritis.
- Vimovo treats the signs and symptoms of rheumatoid arthritis.
- Vimovo treats the signs and symptoms of ankylosing spondylitis.
- Vimovo lowers the risk of stomach ulcers in patients who need ongoing NSAID therapy and are at risk of NSAID-associated gastric ulcers.
- Vimovo is not recommended for treating sudden, short-term pain because its naproxen component is released slowly.
Pregnancy
Contraindicated in pregnancy. Confirm pregnancy status and discuss alternative therapy with the prescriber before dispensing.
- Vimovo is contraindicated during the third trimester of pregnancy because naproxen can cause premature closure of a fetal blood vessel (the ductus arteriosus) and can prolong labour.
- Caution is advised in the first and second trimesters, since NSAIDs are linked to a higher risk of miscarriage and heart-related birth defects when used early in pregnancy.
- Using an NSAID around 20 weeks of pregnancy or later may reduce fetal kidney function, leading to low amniotic fluid (oligohydramnios).
- If Vimovo is used in the second trimester, doctors should monitor amniotic fluid levels closely.
Breastfeeding
- Vimovo is contraindicated in breastfeeding women because of the potential for serious harm to nursing infants from both the naproxen and esomeprazole components.
Geriatrics
- Older adults are more likely to experience serious side effects from Vimovo, including stomach bleeding, ulcers, kidney problems, and heart-related events.
- Most reports of fatal stomach bleeding with NSAIDs occur in elderly or frail patients.
- Doctors may consider a lower starting dose for older patients and monitor them closely.
- Long-term proton pump inhibitor use, including esomeprazole, is linked to a higher risk of bone fractures in patients over 71 years of age.
Pediatrics
- Vimovo should not be used in children or adolescents under 18 years of age, as safety and effectiveness have not been established in this age group.
Dosage & Administration
- The recommended dose of Vimovo is either the 375 mg naproxen/20 mg esomeprazole tablet or the 500 mg naproxen/20 mg esomeprazole tablet, taken twice daily.
- Vimovo tablets must be swallowed whole with water; they must not be split, chewed, or crushed.
- Vimovo should be taken at least 30 minutes before a meal.
- Vimovo is not recommended for patients with severe liver impairment or severe kidney impairment.
- Vimovo does not allow the dose of either naproxen or esomeprazole to be lowered individually; if a lower dose of either component is needed, a different product should be used instead.
- The lowest effective dose should be used for the shortest duration needed to control symptoms.
Overdose
If overdose is suspected, seek emergency medical attention immediately or contact your regional Poison Control Centre without delay.
- There is no specific clinical data on Vimovo overdose; effects would be expected to reflect an overdose of naproxen and esomeprazole taken separately.
- Naproxen overdose can cause drowsiness, dizziness, disorientation, heartburn, stomach pain, nausea, and vomiting.
- Naproxen overdose can cause gastrointestinal bleeding, and in rare cases hypertension, acute kidney failure, slowed breathing, or coma.
- Esomeprazole overdose has caused temporary weakness, loose stools, and nausea in reported cases.
- There is no specific antidote for either component; treatment is supportive and symptomatic.
- Activated charcoal may be considered if the patient is seen within four hours of a large naproxen overdose.
Common side effects
- Indigestion (dyspepsia) may occur.
- Stomach irritation or erosive gastritis may occur.
- Diarrhea may occur.
- Stomach pain may occur.
- Nausea may occur.
- Bloating (abdominal distension) may occur.
- Gas (flatulence) may occur.
- Constipation may occur.
- Headache may occur.
- Altered sense of taste (dysgeusia) may occur.
- Cough may occur.
Serious side effects
Serious side effects require immediate discussion with the prescriber or emergency care.
- Vimovo can cause serious stomach or intestinal ulcers, bleeding, or perforation, which can occur without warning symptoms at any time during treatment.
- Vimovo may increase the risk of heart attack, stroke, or other serious blood clot-related events, which can occur early in treatment and increase with higher doses or longer use.
- Vimovo can cause or worsen high blood pressure.
- Vimovo can cause or worsen congestive heart failure through fluid retention.
- Kidney problems, including acute kidney failure, can occur, especially in dehydrated patients or those with existing kidney disease.
- Long-term esomeprazole use can cause low magnesium, low potassium, or low calcium levels.
- Long-term esomeprazole use can impair vitamin B12 absorption.
- Serious skin reactions, including Stevens-Johnson syndrome, toxic epidermal necrolysis, and DRESS syndrome, have been reported, usually within the first month of treatment.
- Severe liver problems, including hepatitis and liver failure, have been reported rarely.
- Growths in the stomach lining called fundic gland polyps can develop with long-term use, especially beyond one year.
- Seek urgent medical attention for black or bloody stools, vomiting blood, severe stomach pain, chest pain, sudden weakness on one side of the body, or a widespread skin rash with blistering.
Use with caution
- Use with caution in patients with a history of stomach ulcers or gastrointestinal bleeding.
- Use with caution in patients with heart disease or risk factors for heart disease, such as high blood pressure, high cholesterol, diabetes, or smoking.
- Use with caution in patients taking blood thinners such as warfarin, since the combination increases bleeding risk.
- Use with caution in patients with mild to moderate liver or kidney impairment, with regular monitoring of organ function.
- Use with caution in dehydrated patients, since NSAIDs can further reduce kidney blood flow.
- Use with caution in patients taking corticosteroids, SSRIs, or antiplatelet drugs like clopidogrel, due to additive bleeding or ulcer risk.
- Use with caution in patients on long-term therapy, who should have periodic blood counts and liver function tests.
- Use with caution in patients with a history of asthma, nasal polyps, or allergic-type reactions to aspirin or other NSAIDs.
Contraindications
- Contraindicated around the time of coronary artery bypass graft (CABG) surgery.
- Contraindicated in the third trimester of pregnancy.
- Contraindicated in women who are breastfeeding.
- Contraindicated in patients with severe, uncontrolled heart failure.
- Contraindicated in patients with known hypersensitivity to naproxen, esomeprazole, or any ingredient in the tablet.
- Contraindicated in patients with a history of asthma, hives, or allergic reactions after taking aspirin or other NSAIDs.
- Contraindicated in patients with an active stomach or intestinal ulcer, or active gastrointestinal bleeding.
- Contraindicated in patients with bleeding disorders or active bleeding in the brain or gut.
- Contraindicated in patients with inflammatory bowel disease.
- Contraindicated in patients with severe liver impairment or active liver disease.
- Contraindicated in patients with severe kidney impairment or worsening kidney disease.
- Contraindicated in patients with known high blood potassium (hyperkalemia).
- Contraindicated in children and adolescents under 18 years of age.
- Contraindicated in combination with the HIV medication rilpivirine.
Drug interactions
- Vimovo should not be combined with other NSAIDs, including over-the-counter ibuprofen or aspirin used for pain relief, because of added ulcer and bleeding risk without extra benefit.
- Low-dose aspirin for heart protection can be combined with Vimovo, but the combination still increases the risk of stomach bleeding.
- Vimovo can reduce the effectiveness of clopidogrel by lowering levels of its active form; concurrent use should be avoided.
- Vimovo can increase warfarin's effect on bleeding, requiring closer monitoring of blood clotting tests.
- Vimovo taken with methotrexate, especially at high doses, can raise methotrexate levels and increase toxicity risk.
- Vimovo can reduce the blood-pressure-lowering effect of ACE inhibitors, angiotensin receptor blockers, and diuretics, and combined use raises the risk of kidney problems.
- Vimovo can increase lithium blood levels, requiring monitoring when starting or stopping treatment.
- Vimovo taken with cyclosporine or tacrolimus can increase the risk of kidney toxicity.
- Vimovo can increase digoxin blood levels, requiring monitoring for digoxin toxicity.
- Co-administration with atazanavir or nelfinavir is not recommended, as esomeprazole significantly reduces their blood levels.
- Rilpivirine must not be combined with Vimovo, since esomeprazole significantly lowers rilpivirine levels and can cause treatment failure.
- Drugs that strongly affect the CYP2C19 or CYP3A4 liver enzymes, such as voriconazole, clarithromycin, or St. John's wort, can change esomeprazole blood levels.
- SSRIs combined with Vimovo raise the risk of stomach bleeding.
Food interactions
- Vimovo should be taken at least 30 minutes before a meal; food delays the release of the naproxen component and, more importantly, significantly reduces how much esomeprazole is absorbed.
Time of administration
- Take Vimovo at least 30 minutes before eating, ideally at the same times each day, to ensure the esomeprazole component is properly absorbed.
Storage
- Store Vimovo tablets at room temperature, between 15°C and 30°C, in their original container.
Patient take-away
- Vimovo combines a pain and inflammation reliever with a stomach-protecting medication to reduce the risk of NSAID-related ulcers.
- Swallow tablets whole at least 30 minutes before a meal; do not split, crush, or chew them.
- Watch for signs of stomach bleeding, such as black or bloody stools or vomiting blood, and seek care immediately if they occur.
- Vimovo is not for occasional or as-needed pain relief; it is intended for regular, ongoing use as prescribed.
- Tell every healthcare provider you see that you take Vimovo, especially before surgery or when starting a new medication.